File downloaded on 2026-11-16
Source URL: https://medicines.health.europa.eu/veterinary/en/600000031383

EKYFLOGYL 1.8 MG/ML + 8.7 MG/ML GEL FOR HORSES

Ima dovoljenje za promet

- Prednisolone acetate
- Lidocaine hydrochloride monohydrate

Informacije o zdravilu

Ime zdravila:
EKYFLOGYL 1.8 MG/ML + 8.7 MG/ML GEL FOR HORSES

Učinkovina:
Na voljo samo v English
Na voljo samo v English

Ciljne živalske vrste:
Na voljo samo v Bulgarian Spanish Czech Danish German Estonian Greek English French Italian Latvian Lithuanian Hungarian Dutch Romanian Finnish Swedish Icelandic Norwegian

Pot uporabe:
Dermalna uporaba

Podatki o zdravilu

Učinkovina / Jakost:
Na voljo samo v English
2.00 milligram(s) / 1.00 millilitre(s)

Na voljo samo v English
10.70 milligram(s) / 1.00 millilitre(s)

Farmacevtska oblika:

Gel

Karenca glede na pot uporabe:

Dermalna uporaba:

- **Horse**
  - Meat and offal. 10 day
  - Milk. no withdrawal period

Not authorised for use in animals producing milk for human consumption.

Anatomsko-terapevtsko-kemična veterinarska oznaka klasifikacija zdravil, ki se uporabljajo v veterini (ATCvet):

QM02AX99

Pravni status za dobavo/izdajo zdravila:

Zdravilo, ki se izdaja na veterinarski recept

Status dovoljenja za promet z zdravilom:

Valid

Ima dovoljenje za promet v:

Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Na voljo v:

Sweden

Opis ovojnine zdravila:

Na voljo samo v Swedish

Dodatne informacije

Vrsta dovoljenja:

Na voljo samo v English French Croatian Italian Latvian Finnish Swedish Icelandic Norwegian

Pravna podlaga za izdajo dovoljenja za promet z zdravilom:
Na voljo samo v English Italian Latvian Norwegian

Imetnik dovoljenja za promet z zdravilom:
Audevard

Datum dovoljenja za promet z zdravilom:
26/05/2020

Proizvodna mesta, odgovorna za sproščanje serij:
Dopharma France

Pristojni organ:
Swedish Medical Products Agency

Številka dovoljenja za promet z zdravilom:
58101

Datum spremembe statusa dovoljenja za promet:
26/05/2020

Referenčna država članica:
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Številka postopka:
FR/V/0344/001

Zadevne države članice:
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Za poročila o domnevnih neželenih učinkih zdravil za uporabo v veterinaski medicini obiščite stran: www.adrreports.eu/vet

Dokumenti

Povzetek glavnih značilnosti zdravila

Ta dokument ne obstaja v tem jeziku (slovenščina). Lahko ga najdete spodaj v drugem jeziku.

Navodilo za uporabo

Ta dokument ne obstaja v tem jeziku (slovenščina). Lahko ga najdete spodaj v drugem jeziku.

Označevanje

Ta dokument ne obstaja v tem jeziku (slovenščina). Lahko ga najdete spodaj v drugem jeziku.

eu-puar-frv0344001-mr-rpe532-en.pdf